Positive News SentimentPositive News SomaLogic Stock Price, News & Analysis (NASDAQ:SLGC) $2.78 -0.05 (-1.77%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$2.73▼$2.9150-Day Range$1.76▼$2.8352-Week Range$1.73▼$3.79Volume1.70 million shsAverage Volume1.16 million shsMarket Capitalization$522.83 millionP/E RatioN/ADividend YieldN/APrice Target$4.26 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media SomaLogic MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside53.2% Upside$4.26 Price TargetShort InterestHealthy4.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$79,754 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.59) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsBusiness Services Sector99th out of 301 stocksCommercial Physical Research Industry6th out of 12 stocks 3.2 Analyst's Opinion Consensus RatingSomaLogic has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.26, SomaLogic has a forecasted upside of 53.2% from its current price of $2.78.Amount of Analyst CoverageSomaLogic has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.91% of the float of SomaLogic has been sold short.Short Interest Ratio / Days to CoverSomaLogic has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in SomaLogic has recently decreased by 1.66%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSomaLogic does not currently pay a dividend.Dividend GrowthSomaLogic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLGC. Previous Next 3.8 News and Social Media Coverage News SentimentSomaLogic has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Business Services companies.Search Interest2 people have searched for SLGC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added SomaLogic to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SomaLogic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,754.00 in company stock.Percentage Held by Insiders14.90% of the stock of SomaLogic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.35% of the stock of SomaLogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SomaLogic are expected to grow in the coming year, from ($0.59) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SomaLogic is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SomaLogic is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSomaLogic has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SomaLogic Stock (NASDAQ:SLGC)SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.Read More SLGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLGC Stock News HeadlinesNovember 22, 2023 | morningstar.comSomaLogic Inc Class ANovember 22, 2023 | finance.yahoo.comWith 54% ownership of the shares, SomaLogic, Inc. (NASDAQ:SLGC) is heavily dominated by institutional ownersDecember 4, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 12, 2023 | finance.yahoo.comSomaLogic, Inc. (NASDAQ:SLGC) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | markets.businessinsider.comHold Rating Maintained for SomaLogic Amidst Strong Performance and Pending LAB AcquisitionNovember 8, 2023 | benzinga.comRecap: SomaLogic Q3 EarningsNovember 1, 2023 | finance.yahoo.comSomaLogic announces new SomaScan® 11K PlatformOctober 5, 2023 | markets.businessinsider.comHold Rating on SomaLogic Post-Merger: A Strategic Move Shadowed by Stock Performance UncertaintyDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 5, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, APRN, FNCBOctober 4, 2023 | msn.comWhy SomaLogic Stock Dived by 10% on WednesdayOctober 4, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether SomaLogic, Inc. has obtained a Fair Price in its transaction with Standard BioToolsOctober 4, 2023 | benzinga.comSLGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SomaLogic, Inc. Is Fair to ShareholdersOctober 4, 2023 | finance.yahoo.comStandard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences ToolsSeptember 19, 2023 | finance.yahoo.comSomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics marketSeptember 12, 2023 | stockhouse.comSomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumorsSeptember 5, 2023 | stockhouse.comSomaLogic expands agreement with Novo Nordisk to 2025August 18, 2023 | finance.yahoo.comSomaLogic, Inc. (NASDAQ:SLGC) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 17, 2023 | finance.yahoo.comSomaLogic, Inc. (NASDAQ:SLGC) Q2 2023 Earnings Call TranscriptAugust 15, 2023 | seekingalpha.comMore on SomaLogicAugust 15, 2023 | benzinga.comPaysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On TuesdayAugust 15, 2023 | msn.comWhy Shares of SomaLogic Are Up TuesdayAugust 14, 2023 | markets.businessinsider.comSomaLogic Reports Second Quarter 2023 Financial ResultsJuly 24, 2023 | finance.yahoo.comSomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in EuropeJune 16, 2023 | uk.sports.yahoo.comInstitutional investors may adopt severe steps after SomaLogic, Inc.'s (NASDAQ:SLGC) latest 11% drop adds to a year lossesJune 12, 2023 | msn.comSomaLogic, Citogen partner to expand authorized site program in EuropeJune 7, 2023 | finance.yahoo.comSomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?See More Headlines Receive SLGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SomaLogic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:SLGC CUSIPN/A CIK1837412 Webii.cmlifesciencesspac.com Phone303-625-9000FaxN/AEmployees451Year FoundedN/APrice Target and Rating Average Stock Price Target$4.26 High Stock Price Target$7.00 Low Stock Price Target$2.30 Potential Upside/Downside+53.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,160,000.00 Net Margins-159.54% Pretax Margin-159.08% Return on Equity-24.72% Return on Assets-21.62% Debt Debt-to-Equity RatioN/A Current Ratio17.79 Quick Ratio17.29 Sales & Book Value Annual Sales$97.67 million Price / Sales5.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.93Miscellaneous Outstanding Shares188,070,000Free Float160,049,000Market Cap$522.83 million OptionableNot Optionable Beta1.69 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Stephen A. Williams BS (Age 63)MB, Ph.D., Chief Medical Officer Comp: $648.03kMr. Adam Taich (Age 48)Interim CEO Mr. Eliot M. Lurier CPA (Age 65)Interim Chief Financial Officer Mr. Pi Zheng (Age 50)Interim Chief Accounting Officer Dr. Jason Cleveland Ph.D.Chief Technology OfficerDr. Nebojsa Janjic Ph.D. (Age 62)Chief Science Officer Mr. Ruben Gutierrez J.D. (Age 48)General Counsel Ms. Alison Marie Roelke (Age 48)Chief People Officer Dr. Shane Bowen Ph.D.Chief Research & Development OfficerMore ExecutivesKey CompetitorsLuna InnovationsNASDAQ:LUNANational ResearchNASDAQ:NRCYoudaoNYSE:DAOCantaloupeNASDAQ:CTLPBitdeer Technologies GroupNASDAQ:BTDRView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 32,909 shares on 11/30/2023Ownership: 0.058%Deutsche Bank AGBought 14,537 shares on 11/24/2023Ownership: 0.049%Redmile Group LLCSold 1,471,400 shares on 11/15/2023Ownership: 0.212%Legal & General Group PlcBought 20,905 shares on 11/15/2023Ownership: 0.076%AQR Capital Management LLCBought 35,356 shares on 11/15/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions SLGC Stock Analysis - Frequently Asked Questions Should I buy or sell SomaLogic stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SomaLogic in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares. View SLGC analyst ratings or view top-rated stocks. What is SomaLogic's stock price target for 2024? 5 analysts have issued 1 year price targets for SomaLogic's stock. Their SLGC share price targets range from $2.30 to $7.00. On average, they expect the company's share price to reach $4.26 in the next year. This suggests a possible upside of 53.2% from the stock's current price. View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts. How have SLGC shares performed in 2023? SomaLogic's stock was trading at $2.51 at the beginning of 2023. Since then, SLGC shares have increased by 10.8% and is now trading at $2.78. View the best growth stocks for 2023 here. When is SomaLogic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our SLGC earnings forecast. How were SomaLogic's earnings last quarter? SomaLogic, Inc. (NASDAQ:SLGC) released its earnings results on Wednesday, November, 8th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. The business had revenue of $22.05 million for the quarter, compared to analysts' expectations of $20.45 million. SomaLogic had a negative trailing twelve-month return on equity of 24.72% and a negative net margin of 159.54%. What ETF holds SomaLogic's stock ? ARK Genomic Revolution ETF holds 13,104,112 shares of SLGC stock, representing 1.22% of its portfolio. What guidance has SomaLogic issued on next quarter's earnings? SomaLogic updated its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80.00 million-$84.00 million, compared to the consensus revenue estimate of $81.94 million. Who are SomaLogic's major shareholders? SomaLogic's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (6.90%), Sumitomo Mitsui Trust Holdings Inc. (4.66%), Barclays PLC (1.38%), Kent Lake Capital LLC (1.03%), Charles Schwab Investment Management Inc. (0.65%) and Zweig DiMenna Associates LLC (0.33%). Insiders that own company stock include Adam Taich, Alison Marie Roelke and Ruben Gutierrez. View institutional ownership trends. How do I buy shares of SomaLogic? Shares of SLGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SLGC) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SomaLogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.